XML 30 R9.htm IDEA: XBRL DOCUMENT v3.24.2.u1
REVENUE
 6 Months Ended
Jun. 30, 2024
Revenue from Contract with Customer [Abstract]  
REVENUE REVENUE
 
Disaggregated Revenue
 
The following table reflects total revenues for the three and six months ended June 30, 2024 and 2023 (in thousands): 
Three Months Ended June 30,Six Months Ended June 30,
2024202320242023
Product sales, net:
ROLVEDON$15,144 $— $29,622$— 
INDOCIN products6,913 28,075 15,596 58,421 
Sympazan2,668 2,627 5,285 5,129 
Otrexup2,014 3,594 4,896 6,416 
SPRIX2,147 2,373 3,584 4,262 
CAMBIA1,403 1,805 2,660 4,069 
Other products406 1,609 914 3,555 
Total product sales, net30,695 40,083 62,557 81,852 
Royalties and milestone revenue431 723 1,017 1,420 
Other revenue— 185 — 185 
Total revenues$31,126 $40,991 $63,574 $83,457 
Product Sales, net

As a result of the Spectrum Merger, the Company began recognizing ROLVEDON sales in August 2023.

Other product sales, net, for the three and six months ended June 30, 2023 include product sales for OXAYDO and Zipsor. As the Company ceased OXAYDO product sales beginning in September 2023, other net product sales for the three and six months ended June 30, 2024 represent only net product sales of Zipsor.
Royalties and Milestone Revenue

In November 2010, the Company entered into a license agreement granting Tribune Pharmaceuticals Canada Ltd. (now known as Miravo Pharmaceuticals, or “Miravo”) the rights to commercially market CAMBIA in Canada. Miravo independently contracts with manufacturers to produce a specific CAMBIA formulation in Canada. The Company recognized royalties revenue related to the CAMBIA licensing agreement of $0.4 million and $1.0 million for the three and six months ended June 30, 2024, respectively, and $0.4 million and $1.0 million for the three and six months ended June 30, 2023, respectively.

The Company recognized no milestone revenue associated with the completion of certain service milestones for the three and six months ended June 30, 2024, and $0.3 million and $0.5 million and for the three and six months ended June 30, 2023, respectively.